Press Release - Audited Financial Results - Q4 and FY ended 31st March 2026.
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vimta Labs reported FY26 total income of Rs. 4,163 Mn, a 19.5% YoY increase from Rs. 3,482 Mn in FY25. Q4 FY26 revenue was Rs. 1,120 Mn, up 16.6% YoY and 11.5% QoQ. EBITDA for FY26 stood at Rs. 1,489 Mn with margins at 35.8%, slightly down from 36.2% in FY25. PAT (continued operations) was Rs. 775 Mn, up 16.1% YoY, with PAT margin at 18.6% versus 19.2% in FY25. Basic EPS for FY26 was Rs. 17.4, up 15.9% YoY. The company notes it sold its Diagnostic and Pathological services business to Thyrocare Technologies (completed October 11, 2024), with prior period figures regrouped for comparability.
Strong revenue growth of ~20% driven by Pharma and Food divisions. However, slight compression in EBITDA and PAT margins YoY indicates some margin pressure despite volume growth. The business divestiture may have affected the revenue and margin base comparability.